TAK - Takeda Pharmaceutical gives H1 results raised FY guidance
2023-10-26 02:26:28 ET
More on Takeda Pharmaceutical
- Takeda: Why I'm Staying Bearish On This Generic Drug Dividend Play
- Takeda: Innovative But Volatile, Fairly Priced For The Risk (Downgrade)
- Takeda fails in second Phase 3 trial for CPF therapy Alofisel
- Takeda to voluntarily pull lung cancer drug Exkivity from U.S. market
- Seeking Alpha’s Quant Rating on Takeda Pharmaceutical
For further details see:
Takeda Pharmaceutical gives H1 results, raised FY guidance